An innovator with a large secondary patent estate can list dozens of patents, requiring the biosimilar developer to assess each one for infringement and validity before the litigation phase begins
The only clinically relevant difference between treatments was the higher frequency of gastrointestinal related adverse events with IcoSema versus icodec or semaglutide alone, which can be mitigated by appropriate dosing recommendations for IcoSema, as discussed above
Lake J, Bortolasci CC, Stuart AL, Pasco JA, Kidnapillai S, Spolding B, et al
The study suggests that when adherence is supported, oral naltrexone may work as well as the injectable formulation
Matta, S
[DOI] [PMC free article] [PubMed] [Google Scholar] 41.Kalafateli AL, Vallf D, Jrnulf JW, Heilig M, Jerlhag E